Your browser is no longer supported. Please, upgrade your browser.
Settings
VSAR Versartis, Inc. daily Stock Chart
VSAR [NASD]
Versartis, Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own3.60% Shs Outstand36.58M Perf Week-2.86%
Market Cap62.19M Forward P/E- EPS next Y-3.90 Insider Trans478.69% Shs Float31.97M Perf Month-19.05%
Income-70.50M PEG- EPS next Q-1.06 Inst Own49.70% Short Float2.38% Perf Quarter9.68%
Sales40.00M P/S1.55 EPS this Y-7.60% Inst Trans15.44% Short Ratio1.20 Perf Half Y-1.45%
Book/sh1.91 P/B0.89 EPS next Y3.70% ROA-37.80% Target Price4.00 Perf Year-89.79%
Cash/sh1.85 P/C0.92 EPS next 5Y- ROE-54.00% 52W Range1.35 - 22.10 Perf YTD-22.73%
Dividend- P/FCF- EPS past 5Y-42.60% ROI-132.90% 52W High-92.53% Beta1.88
Dividend %- Quick Ratio17.00 Sales past 5Y- Gross Margin- 52W Low22.22% ATR0.10
Employees28 Current Ratio17.00 Sales Q/Q- Oper. Margin- RSI (14)32.58 Volatility6.63% 5.76%
OptionableYes Debt/Eq0.11 EPS Q/Q73.70% Profit Margin-93.70% Rel Volume0.15 Prev Close1.70
ShortableNo LT Debt/Eq0.11 EarningsAug 02 AMC Payout- Avg Volume632.75K Price1.65
Recom3.00 SMA20-8.78% SMA50-17.23% SMA200-10.54% Volume9,566 Change-2.94%
Mar-02-18Downgrade Canaccord Genuity Buy → Hold $9 → $5
Sep-25-17Downgrade Citigroup Buy → Neutral
Sep-22-17Downgrade SunTrust Buy → Hold
Sep-22-17Downgrade Piper Jaffray Overweight → Neutral
Sep-22-17Downgrade Barclays Overweight → Equal Weight $28 → $4
May-05-17Initiated Cantor Fitzgerald Overweight $34
Mar-09-17Initiated Barclays Overweight $28
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-02-16Initiated SunTrust Buy $25
Oct-04-16Initiated Piper Jaffray Overweight
Dec-17-15Downgrade Credit Suisse Neutral → Underperform
Aug-20-15Initiated Credit Suisse Neutral
Aug-13-15Initiated Morgan Stanley Equal-Weight $17
Jul-07-15Reiterated Canaccord Genuity Buy $20 → $28
Apr-14-15Initiated Sun Trust Rbsn Humphrey Buy $50
Apr-15-14Initiated Canaccord Genuity Buy $36
Aug-07-18 05:51PM  Versartis: 2Q Earnings Snapshot Associated Press
04:15PM  Versartis Reports Second Quarter 2018 Financial Results and Reviews Recent Developments GlobeNewswire
Jun-05-18 07:25AM  Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy ACCESSWIRE +9.68%
07:20AM  Free Technical Research on Versartis and Three More Biotech Equities ACCESSWIRE
Jun-04-18 08:20AM  Versartis's stock soars after merger deal with Aravive to create oncology-focused company MarketWatch +6.90%
08:00AM  Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics GlobeNewswire
May-09-18 05:11AM  Versartis: 1Q Earnings Snapshot Associated Press -5.00%
May-08-18 04:15PM  Versartis Reports First Quarter 2018 Financial Results GlobeNewswire -7.69%
Apr-20-18 07:30AM  Detailed Research: Economic Perspectives on PacWest, HD Supply, Limelight Networks, Clean Harbors, Versartis, and Pacira Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-26-18 04:05PM  Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire
Mar-06-18 07:48PM  Versartis Inc (VSAR) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Mar-01-18 06:11PM  Versartis posts 4Q profit Associated Press
04:05PM  Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
Feb-14-18 08:30AM  Investor Expectations to Drive Momentum within Amerco, Caesars Entertainment, Air Products and Chemicals, Consolidated Edison, Teligent, and Versartis Discovering Underlying Factors of Influence GlobeNewswire
Feb-05-18 08:51AM  Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock? Zacks
Dec-04-17 08:10AM  Todays Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Versartis ACCESSWIRE -10.00%
Dec-01-17 09:35AM  Versartis Pops, DBV Wild Ride Continues -- Biotech Movers TheStreet.com +15.38%
Nov-30-17 08:00AM  Report: Exploring Fundamental Drivers Behind Amerco, Caesars Entertainment, Air Products and Chemicals, Consolidated Edison, Teligent, and Versartis New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-27-17 09:35AM  Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers TheStreet.com -17.39%
Oct-26-17 06:57PM  Versartis reports 3Q loss Associated Press
04:05PM  Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
04:05PM  Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions GlobeNewswire
Sep-25-17 04:04PM  Kroger, Versartis Locked in Mondays 52-Week Low Club 24/7 Wall St. -8.41%
12:54PM  Company News For Sep 25, 2017 Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Exelixis and Versartis ACCESSWIRE
Sep-24-17 10:15AM  Ascendis Pharma shares surge 42% as competitor Versartis plummets 85% on failed trial MarketWatch
Sep-22-17 04:30PM  Why Versartis, Wayfair, and Compass Minerals Slumped Today Motley Fool -87.62%
04:04PM  Versartis, Intercept Pharma Plunge into Fridays 52-Week Low Club 24/7 Wall St.
02:44PM  This Trial Failure Dropped Versartis Inc 86.6% and Lifted Ascendis Pharma 51.4% Motley Fool
12:13PM  Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers TheStreet.com
10:45AM  Is This the Death of Versartis? 24/7 Wall St.
10:42AM  T-Mobile, Sprint merger reportedly near, HPE to cut jobs, Finish Line falls Yahoo Finance
10:40AM  T-Mobile, Sprint merger reportedly closer, HPE to cut jobs, Finish Line falls Yahoo Finance Video
08:49AM  Overly complacent investors may be in for a rude Fed wake-up call MarketWatch
08:48AM  Markets brush off North Korea threat Yahoo Finance
08:45AM  Ascendis Pharma shares surge 42% on competitor's flop MarketWatch
07:33AM  Human Growth Drug Flop Sends This Biotech Crashing 83% Investor's Business Daily
Sep-21-17 09:24PM  Is Versartis Inc (VSAR) Undervalued? Simply Wall St.
05:59PM  Versartis growth hormone drug fails key study, shares sink Reuters
05:04PM  Versartis shares down 82% MarketWatch
04:30PM  Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint GlobeNewswire
08:44AM  Versartis, Inc. (VSAR) in Focus: Stock Moves 11.5% Higher Zacks
Sep-18-17 08:35AM  Implied Volatility Surging for Versartis (VSAR) Stock Options Zacks +6.27%
Sep-07-17 04:05PM  Versartis Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017 GlobeNewswire +7.44%
Sep-05-17 04:05PM  Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs GlobeNewswire
Aug-31-17 08:50AM  Implied Volatility Surging for Versartis (VSAR) Stock Options Zacks
Aug-03-17 08:38AM  Options Traders Expect Huge Moves in Versartis (VSAR) Stock Zacks
Aug-02-17 08:30AM  Versartis to Present at the Canaccord Genuity Growth Conference GlobeNewswire
Jul-28-17 08:05PM  Versartis reports 2Q loss Associated Press
Jul-27-17 04:05PM  Versartis Reports Second Quarter 2017 Financial Results GlobeNewswire
Jun-21-17 08:52AM  Is the Options Market Predicting a Spike in Versartis (VSAR) Stock? Zacks +5.28%
Jun-01-17 08:30AM  Versartis Appoints Eric Dobmeier to Board of Directors GlobeNewswire +6.51%
May-26-17 12:09PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Versartis Inc. Business Wire
May-22-17 08:15AM  Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology GlobeNewswire
Apr-27-17 06:04PM  Versartis reports 1Q loss Associated Press
04:05PM  Versartis Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-26-17 11:42AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Versartis Inc. - VSAR Accesswire
Apr-25-17 08:30AM  Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations GlobeNewswire
Apr-03-17 11:32AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
11:20AM  Versartis Announces Three Year Somavaratan Data at ENDO 2017 Showing Safety and Efficacy in Line with Historical U.S. Daily rhGH Data in Pediatric GHD PR Newswire
07:30AM  Versartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017 PR Newswire
Mar-30-17 04:56PM  Insider Invests in Versartis
Mar-23-17 04:22PM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga
08:30AM  Versartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency GlobeNewswire
Mar-22-17 09:30AM  Rennova Health and Versartis Have Different Reasons for Optimism Accesswire
Mar-21-17 10:25AM  5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts 24/7 Wall St.
Mar-16-17 01:04PM  VERSARTIS, INC. Financials
Mar-15-17 08:30AM  Versartis Appoints Tracy Woody as Chief Commercial Officer GlobeNewswire
Mar-10-17 07:17AM  VERSARTIS, INC. Files SEC form 10-K, Annual Report
Mar-09-17 12:27PM  Coverage initiated on Versartis by Barclays
09:14AM  Barclays Sees 40% Upside In Versartis Over Next Year Benzinga
Mar-02-17 08:30AM  Versartis Announces Data on Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Late-Breaker Presentation at ENDO 2017 GlobeNewswire
Mar-01-17 04:36PM  Versartis to Present at Cowen & Co. Annual Healthcare Conference and Barclays Global Healthcare Conference GlobeNewswire
Feb-25-17 12:26AM  [$$] The Length of a Biotech Patent's Life, Corrected at Barrons.com
Feb-23-17 06:00AM  These Small Biotechs Are Poised to Go Higher at Investopedia +8.21%
Feb-21-17 04:51PM  Versartis reports 4Q loss +15.90%
04:31PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Fourth Quarter 2016 Financial Results GlobeNewswire
Feb-18-17 01:26AM  [$$] Why Biotech Looks Like a Good Bet in 2017 at Barrons.com
Feb-15-17 02:04PM  Twitter Is One of Five Stocks Insiders Really Love Right Now
Jan-31-17 05:02PM  VERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers +10.00%
08:30AM  Versartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer GlobeNewswire
Jan-30-17 06:56PM  Versartis Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017 GlobeNewswire -9.09%
Jan-13-17 11:00AM  Versartis' Pipeline Holds Big Promise
Jan-09-17 08:40AM  Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
Jan-08-17 10:10AM  Huge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix, Amicus Therapeutics and More
Jan-05-17 08:20AM  Versartis (VSAR) Shares March Higher, Can It Continue?
Jan-04-17 02:47PM  5 Stocks Insiders Are Loading Up On +7.38%
Dec-28-16 04:32PM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-04-16 03:56PM  150% Surge in Smart Money Ownership of Versartis Inc (VSAR): What Have They Discovered? at Insider Monkey
Nov-29-16 12:41PM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-28-16 02:23PM  Versartis, Inc. :VSAR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 -5.97%
Nov-07-16 07:30AM  Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society GlobeNewswire +6.04%
Nov-04-16 05:19PM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report
Nov-03-16 06:48PM  Versartis reports 3Q loss -5.56%
04:12PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-31-16 08:30AM  Versartis to Present at Two Investor Conferences in November GlobeNewswire -9.80%
Oct-17-16 09:00AM  Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology Marketwired
Oct-14-16 04:20PM  VERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Westberg PaulSVP and Chief Business OfficerJun 15Sale2.306121,408225,124Jun 19 04:54 PM
Haas KevinVP, Finance and PAOJun 15Sale2.3014332978,075Jun 19 04:52 PM
AKKARAJU SRINIVASDirectorJun 13Buy2.1353,018112,9282,682,554Jun 15 09:44 PM
AKKARAJU SRINIVASDirectorJun 08Buy2.00231,580463,1602,629,536Jun 08 06:34 PM
AKKARAJU SRINIVASDirectorJun 07Buy1.85163,224301,9642,397,956Jun 08 06:34 PM
AKKARAJU SRINIVASDirectorJun 06Buy1.74660,6811,149,5852,234,732Jun 08 06:34 PM
Shepard JayPresident and CEOMay 22Sale1.509,23213,848593,066May 23 05:42 PM
Stout Jay SSVP, Technical OperationsApr 24Sale1.554,8547,524185,646Apr 25 06:10 PM
Woody Tracy MChief Commercial OfficerMar 23Sale1.754,3457,604215,755Mar 26 06:54 PM
Haas KevinVP, Finance and PAOFeb 08Sale1.801,5992,87878,218Feb 12 05:27 PM
Shepard JayPresident and CEOFeb 08Sale1.8014,44626,003602,298Feb 12 05:25 PM
Ward ShaneSVP and General CounselFeb 08Sale1.804,1187,412201,556Feb 12 05:23 PM
Westberg PaulSVP and Chief Business OfficerFeb 08Sale1.805,3559,639225,736Feb 12 05:20 PM
AKKARAJU SRINIVASDirectorDec 05Buy2.0042,89585,7901,547,896Dec 05 07:38 PM
AKKARAJU SRINIVASDirectorDec 04Buy2.21513,8721,135,6571,505,001Dec 05 07:38 PM
AKKARAJU SRINIVASDirectorDec 01Buy2.13419,700893,961991,129Dec 05 07:38 PM
Westberg PaulSVP and Chief Business OfficerOct 19Sale2.551,3263,381125,191Oct 23 05:02 PM
Ward ShaneSVP and General CounselOct 19Sale2.557761,97992,574Oct 23 05:01 PM
Hislop ColinChief Medical OfficerOct 19Sale2.556671,70123,833Oct 23 04:59 PM
Brumm Joshua TCOO and CFOOct 19Sale2.551,3263,381201,269Oct 23 04:58 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 22Sale3.201,650,0005,281,7502,099,563Sep 25 04:07 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 21Sale3.61480,0001,731,8023,749,563Sep 25 04:07 PM